Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azetukalner in Major Depressive Disorder
NCT06922110Phase 3Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in major depressive disorder (MDD), sponsored by Xenon Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Events of Clinical Interest at 60 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06922110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922110.